| 1 |
34700030 | Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer. | 2022 |
1 |
| 2 |
35197630 | Effective drug combinations in breast, colon and pancreatic cancer cells. | 2022 Mar |
1 |
| 3 |
35489740 | Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen. | 2022 May |
1 |
| 4 |
32743640 | Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations. | 2021 May 20 |
1 |
| 5 |
33747719 | Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. | 2021 Mar |
1 |
| 6 |
34281853 | Clinical Impact of Primary Tumor Location and RAS, BRAF V600E, and PIK3CA Mutations on Epidermal Growth Factor Receptor Inhibitor Efficacy as Third-line Chemotherapy for Metastatic Colorectal Cancer. | 2021 Aug |
1 |
| 7 |
32829105 | Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST). | 2020 Oct |
1 |
| 8 |
32863385 | Phase 2 study of irinotecan plus cetuximab rechallenge as third-line treatment in KRAS wild-type metastatic colorectal cancer: JACCRO CC-08. | 2020 Nov |
2 |
| 9 |
33120790 | Trifluridine/tipiracil in combination with local therapy may be a favorable option for refractory metastatic colorectal cancer patients: A case report. | 2020 Oct 23 |
1 |
| 10 |
30307354 | Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. | 2019 |
1 |
| 11 |
30415007 | Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells. | 2019 Mar 10 |
1 |
| 12 |
30840064 | Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. | 2019 May 1 |
1 |
| 13 |
31126331 | CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial. | 2019 May 24 |
1 |
| 14 |
31363167 | A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients. | 2019 Aug |
1 |
| 15 |
28229371 | Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records. | 2018 Sep |
1 |
| 16 |
28747102 | Irinotecan-induced muscle twitching from a possible drug interaction: A case report. | 2018 Oct |
1 |
| 17 |
29169974 | A Prospective, Multicenter Phase II Study of the Efficacy and Feasibility of 15-minute Panitumumab Infusion Plus Irinotecan for Oxaliplatin- and Irinotecan-refractory, KRAS Wild-type Metastatic Colorectal Cancer (Short Infusion of Panitumumab Trial). | 2018 Mar |
1 |
| 18 |
29908105 | Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. | 2018 Aug |
1 |
| 19 |
26245851 | Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients. | 2017 Apr |
1 |
| 20 |
28025786 | EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. | 2017 Jul |
1 |
| 21 |
28081962 | Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy. | 2017 Jun |
2 |
| 22 |
28414297 | Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. | 2017 May 1 |
1 |
| 23 |
28711984 | Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. | 2017 Sep |
1 |
| 24 |
26551156 | Mathematical modeling of drug resistance due to KRAS mutation in colorectal cancer. | 2016 Jan 21 |
1 |
| 25 |
26891420 | A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. | 2016 Jul 1 |
1 |
| 26 |
27143148 | Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. | 2016 Jun |
1 |
| 27 |
27229742 | A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study). | 2016 |
1 |
| 28 |
27246726 | ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. | 2016 May 31 |
1 |
| 29 |
27313739 | Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study). | 2016 Jun |
1 |
| 30 |
27354619 | Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer. | 2016 Jul |
1 |
| 31 |
27468920 | Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study). | 2016 Sep |
1 |
| 32 |
25236593 | Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. | 2015 Feb |
1 |
| 33 |
25605843 | Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. | 2015 Mar 1 |
1 |
| 34 |
26486455 | Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan. | 2015 Oct 20 |
1 |
| 35 |
23821377 | EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. | 2014 Sep |
1 |
| 36 |
24407191 | Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. | 2014 Mar 4 |
1 |
| 37 |
24468885 | Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. | 2014 Jun |
3 |
| 38 |
24619075 | Comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'. | 2014 Dec 9 |
1 |
| 39 |
24619079 | Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'. | 2014 Dec 9 |
1 |
| 40 |
24683007 | Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. | 2014 May |
1 |
| 41 |
24692733 | Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. | 2014 Apr |
2 |
| 42 |
24764659 | Role of cetuximab in first-line treatment of metastatic colorectal cancer. | 2014 Apr 21 |
1 |
| 43 |
24772300 | KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin-or irinotecan-based treatment. | 2014 May |
1 |
| 44 |
24968756 | Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). | 2014 |
3 |
| 45 |
25515240 | DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. | 2014 Dec 16 |
2 |
| 46 |
23041588 | Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. | 2013 Feb |
2 |
| 47 |
23298313 | Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. | 2013 Apr |
1 |
| 48 |
23328486 | A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan. | 2013 |
2 |
| 49 |
23359181 | Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. | 2013 Sep |
3 |
| 50 |
23514584 | Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: outcome and results of KRAS mutational analysis in plasma. | 2013 Jun |
1 |